In the last century crystal engineering gained more attention within the scientific community, due to its many potential applications. Notable among these are the enhancement of the physicochemical properties of drugs, the development of controlled drug release systems, the creation of organic semiconductors, the design of chemical sensors, and the production of controlled-release fertilizers. Engineering crystal structures with tailored properties implies that their design and synthesis is guided by precise control of intermolecular interactions that occur between molecules within crystal lattice. In particular, the pharmaceutical sector finds very promising a specific crystal engineering strategy: the use of cocrystals. Pharmaceutical co-crystals are defined as crystalline structures composed of at least an active pharmaceutical ingredient (API) and one or more partner molecules ,in a stoichiometric ratio, hereinafter referred to as “coformers”.